Epistaxis risk factors: Difference between revisions
m Bot: Removing from Primary care |
Amir Bagheri (talk | contribs) |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Epistaxis}} | {{Epistaxis}} | ||
'''Editor in Chief''': [[User:Ludi|Liudvikas Jagminas, M.D., FACEP]] [mailto:LJagminas@mhri.org] Phone: 401-729-2419 | '''Editor in Chief''': [[User:Ludi|Liudvikas Jagminas, M.D., FACEP]] [mailto:LJagminas@mhri.org] Phone: 401-729-2419 | ||
== Overview == | ==Overview== | ||
Occasionally, nosebleeds may indicate other disorders such as bleeding disorders or high blood pressure. Frequent nosebleeds may also be a sign of hereditary hemorrhagic telangiectasia (also called HHT or Osler-Weber-Rendu syndrome). Blood thinners such as [[Coumadin]], [[Plavix]], or [[aspirin]] may cause or worsen nosebleeds. | Occasionally, nosebleeds may indicate other disorders such as bleeding disorders or high blood pressure. Frequent nosebleeds may also be a sign of hereditary hemorrhagic telangiectasia (also called HHT or Osler-Weber-Rendu syndrome). Blood thinners such as [[Coumadin]], [[Plavix]], or [[aspirin]] may cause or worsen nosebleeds. | ||
==Risk Factors== | |||
*'''Vascular abnormalities''':.<ref name="KrulewitzFix2019">{{cite journal|last1=Krulewitz|first1=Neil Alexander|last2=Fix|first2=Megan Leigh|title=Epistaxis|journal=Emergency Medicine Clinics of North America|volume=37|issue=1|year=2019|pages=29–39|issn=07338627|doi=10.1016/j.emc.2018.09.005}}</ref> <ref name="DouglasWormald2007">{{cite journal|last1=Douglas|first1=Richard|last2=Wormald|first2=Peter-John|title=Update on epistaxis|journal=Current Opinion in Otolaryngology & Head and Neck Surgery|volume=15|issue=3|year=2007|pages=180–183|issn=1068-9508|doi=10.1097/MOO.0b013e32814b06ed}}</ref> | |||
**[[Hereditary Hemorrhagic Telangiectasia]] | |||
**Congestive hearth failure | |||
**[[Granulomatosis with polyangitis]] | |||
*'''Truama''' | |||
*'''Infections''' | |||
*'''Coagulopathies:''' | |||
**[[Anticoagulants]] | |||
**[[Antiplatelet]] | |||
**[[von Willebrand disease]] | |||
**[[Leukemia]] | |||
**Other [[medications]] causing [[coagulopathy]] | |||
There is not enough evidence that hypertension is a risk factor for epistaxis. The role of lowering blood pressure to control and prevent epistaxis remains controversial. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 19:26, 20 September 2020
|
Epistaxis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Epistaxis risk factors On the Web |
|
American Roentgen Ray Society Images of Epistaxis risk factors |
|
Risk calculators and risk factors for Epistaxis risk factors |
Editor in Chief: Liudvikas Jagminas, M.D., FACEP [1] Phone: 401-729-2419
Overview
Occasionally, nosebleeds may indicate other disorders such as bleeding disorders or high blood pressure. Frequent nosebleeds may also be a sign of hereditary hemorrhagic telangiectasia (also called HHT or Osler-Weber-Rendu syndrome). Blood thinners such as Coumadin, Plavix, or aspirin may cause or worsen nosebleeds.
Risk Factors
- Vascular abnormalities:.[1] [2]
- Hereditary Hemorrhagic Telangiectasia
- Congestive hearth failure
- Granulomatosis with polyangitis
- Truama
- Infections
- Coagulopathies:
There is not enough evidence that hypertension is a risk factor for epistaxis. The role of lowering blood pressure to control and prevent epistaxis remains controversial.
References
- ↑ Krulewitz, Neil Alexander; Fix, Megan Leigh (2019). "Epistaxis". Emergency Medicine Clinics of North America. 37 (1): 29–39. doi:10.1016/j.emc.2018.09.005. ISSN 0733-8627.
- ↑ Douglas, Richard; Wormald, Peter-John (2007). "Update on epistaxis". Current Opinion in Otolaryngology & Head and Neck Surgery. 15 (3): 180–183. doi:10.1097/MOO.0b013e32814b06ed. ISSN 1068-9508.